Actively Recruiting
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Led by Université Catholique de Louvain · Updated on 2026-05-15
150
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how the immune system responds to myeloproliferative neoplasms (MPN) in adults who have or are suspected to have MPN. This observational study aims to identify specific immune cells, called T cells, that can recognize MPN cells and to find targets on these cancer cells that may be useful for future immune-based treatments. The study focuses on adults with conditions like polycythemia vera, essential thrombocythemia, primary myelofibrosis, post-PMF, or unclassifiable MPN, and also includes healthy donors for comparison. Participants will provide blood and bone marrow samples, which researchers will analyze using laboratory methods including genetic sequencing, cell analysis, and cell culture experiments. These tests will help identify T cell receptors and tumor antigens linked to MPN cells. The study will continue for about 10 years to thoroughly monitor and identify these immune responses. During the study, participants will contribute samples that enable detailed research on immune cells and genetic material related to MPN. Researchers will measure the presence of MPN-specific CD8+ T cell clonotypes and their corresponding tumor antigens throughout the study period. Participants will not receive direct medical benefits, but their involvement will support the development of future immune-based therapies. The study will last approximately 10 years, allowing long-term observation and analysis.
CONDITIONS
Brief Title
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults previously diagnosed or suspected of having polycythemia vera, essential thrombocythemia, pre-primary myelofibrosis, overt primary myelofibrosis, or unclassifiable myeloproliferative neoplasm
- Adults not previously diagnosed with a blood disorder can participate as controls
You will not qualify if you...
- Patients with any other hematological malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 10 years
Participants are observed over an extended period to identify specific immune responses related to myeloproliferative neoplasm.
Trial Site Locations
Total: 1 location
1
de Duve Institute, UCLouvain
Brussels, Woluwe, Belgium, 1200
Actively Recruiting
Research Team
S
Sophie Lucas
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here